High serum HTATIP2/TIP30 level in serous ovarian cancer as prognostic or diagnostic marker


KUMTEPE Y., HALICI Z., Sengul O., Kunak C. S., BAYIR Y., Kilic N., ...Daha Fazla

European Journal of Medical Research, cilt.18, sa.1, 2013 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 1
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1186/2047-783x-18-18
  • Dergi Adı: European Journal of Medical Research
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: adenocarcinoma, HTATIP2/TIP30, ovarian cancer
  • Ankara Üniversitesi Adresli: Evet

Özet

Background: Human HIV-1 TAT interactive protein 2 (HTATIP2/TIP30) is an evolutionarily conserved gene that is expressed ubiquitously in human tissues and some tumor tissues. This protein has been found to be associated with some gynecological cancers; as such, this study aimed to investigate blood HTATIP2/TIP30 levels in patients with ovarian cancer. Methods. Twenty-three women with ovarian cancer and 18 patients with various non-cancerous gynecological complaints (for example, dysfunctional uterine bleeding, fibroids, and urinary incontinence) were included in the study. The pathological diagnosis of ovarian cancer was adenocarcinoma. HTATIP2/TIP30 concentration in the patients' blood samples was determined using ELISA kits. Results: The HTATIP2/TIP30 level was significantly higher in the cancer group than in the control group (1.84 ± 0.82 versus 0.57 ± 0.13 ng/ml, mean ± SD). Conclusions: We demonstrated the potential role of HTATIP2/TIP30 in ovarian cancer for the first time, thereby enlightening future studies targeting HTATIP2/TIP30 in ovarian cancer treatment, diagnosis, and prevention. © 2013 Kumtepe et al.; licensee BioMed Central Ltd.